Role of cilostazole and aspirin in peripheral vascular disease in Diabetics

Comparison of Cilostazole and Aspirin in treatment of peripheral vascular disease in diabetics. Comparative study. Fatima Memorial Hospital, Shadman, Lahore from October 2005 to July 2006. Fifty five diabetics patients were included in the study, regardless of presence or absence of symptoms and signs of peripheral vascular diseases. Complications of diabetes such as neuropathy, retinopathy, diabetic amytrophy and foot deformities were assessed in detail. Patients who had peripheral vascular diseases with [Doppler] ankle brachial index measurement were divided randomly given cilostazole, [pletaal] and aspirin. Ankle brachial index measurement was again done after three months of therapy. One way Anova was used to test the efficacy of aspirin and cilestazole. The F ratio [P<0.05] showed a significant difference between three groups and post HOC test showed cilostazole is more effective. Cilostazole, phosphodiestrase III inhibitor improves symptoms, signs and ABI measurements in diabetic patients when given for three months. However aspirin had no significant effect on improvement of such parameters